Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Gouty Patients
NCT06924658Phase 2Recruiting
- Start
- Apr 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liquid metformin (Aspargo Labs) in gout (2 arms). Primary endpoint: Clinical assessment of disease activity at 3 months. Started Apr 2025; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
gout
Beyond the preview
Go deeper on NCT06924658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06924658.